Since FoxO1 synergistically enhances the NF-κB signaling pathway by binding to the insulin response element, the DNA motif of NF-κB target genes, Rh1-derived therapeutic potential on NAFLD is based on FoxO1-modulation-mediated NF-κB inactivation [112]. Here, FOXO1 is linked to metabolic dysfunction-associated steatotic liver disease.